MGI Sequencing Platform Strengthens Latvia's COVID 19 Response

Описание: MGI’s proprietary DNBSEQ™ sequencing platform* is proudly supporting the Latvian Biomedical Research and Study Centre (BMC)’s COVID-19 study using genome-sequencing to support Latvia’s COVID-19 pandemic response and surveillance. MGI Latvia, a subsidiary of MGI, supplied the instruments including DNBSEQ-G400 High-throughput Genetic Sequencer* and MGISP-960 High-throughput Automated Sample Preparation System and provides BMC with on-the-ground support in coordination with the Shenzhen Headquarters. MGI Latvia acts as a hub of research and development, production, logistics and specialized training for MGI’s business development in Europe and other international regions. The 7,500m2 facility has a Global Product Application Demo Centre and a state-of-art Sequencing Centre. For more information please visit MGI website or connect with us on LinkedIn, Twitter, or YouTube.